Fala, L. (2015). Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits.
Chicago Style CitationFala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.
Cita MLAFala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.
Atenció: Aquestes cites poden no estar 100% correctes.